Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Notice of Meeting, 25877-25878 [2014-10299]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 87 / Tuesday, May 6, 2014 / Notices
sroberts on DSK5SPTVN1PROD with NOTICES
HHS Ref. No.: E–326–2008/0–PCT–02
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian-Kang Jiang, and
Matthew Boxer (NCATS)
3. Australian Patent Application No.
2009303335, filed October 9, 2009
HHS Ref. No.: E–326–2008/0–AU–03
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian-Kang Jiang, and
Matthew Boxer (NCATS)
4. Canadian Patent Application No.
2,740,148, filed October 9, 2009
HHS Ref. No.: E–326–2008/0–CA–04
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian-Kang Jiang, and
Matthew Boxer (NCATS)
5. European Patent Application No.
09740795.1, filed October 9, 2009
HHS Ref. No.: E–326–2008/0–EP–05
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian-Kang Jiang, and
Matthew Boxer (NCATS)
6. Japanese Patent Application No. 531221–
2011, filed October 9, 2009
HHS Ref. No.: E–326–2008/0–JP–06
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian-Kang Jiang, and
Matthew Boxer (NCATS)
7. U.S. Patent Application No. 13/123,297,
filed October 9, 2009
HHS Ref. No.: E–326–2008/0–US–07
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian-Kang Jiang, and
Matthew Boxer (NCATS)
8. U.S. Patent Application No. 13/433,656,
filed March 29, 2012
HHS Ref. No.: E–326–2008/0–US–08
Titled: Activators of Pyruvate Kinase
Inventors: Craig J. Thomas, Douglas S.
Auld, James Inglese, Amanda P.
Skoumbourdis, Jian- Kang Jiang, and
Matthew Boxer (NCATS)
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
territory of the prospective Start-up
Exclusive Evaluation Option License
Agreement may be worldwide, and the
field of use may be limited to ‘‘Use of
PK–M2 activators for treatment of
cancer in humans.’’
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, TeamedOn
International will have the exclusive
right to execute a Start-up Exclusive
Patent License Agreement which will
supersede and replace the Start-up
Exclusive Evaluation Option License
Agreement, with no greater field of use
and territory than granted in the Start-
VerDate Mar<15>2010
17:34 May 05, 2014
Jkt 232001
up Exclusive Evaluation Option License
Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before May
21, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated Start-up Exclusive
Evaluation Option License Agreement
should be directed to: Suryanarayana
Vepa, Ph.D., J.D., Senior Licensing and
Patenting Manager, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–5020; Facsimile:
(301) 402–0220; Email: vepas@
mail.nih.gov. A signed confidentiality
nondisclosure agreement will be
required to receive copies of any patent
applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: The fetal
form of Pyruvate Kinase, called PK–M2,
is expressed in all cancer cells but is
normally inactive. The products and
methods sought in the prospective
evaluation option license agreement
activate PK–M2 and result in inhibition
of tumor development. This invention
relates to products and methods of
administering PK–M2 activators of
various types and methods of treating
cancer and diseases susceptible to PK–
M2 activators. The prospective Start-up
Exclusive Evaluation Option License
Agreement is being considered under
the small business initiative launched
on October 1, 2011 and will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR Part 404. The
prospective Start-up Exclusive
Evaluation Option License Agreement
and a subsequent Start-up Exclusive
Patent License Agreement may be
granted unless the NIH receives written
evidence and argument, within fifteen
(15) days from the date of this published
notice, that establishes that the grant of
the contemplated Start-up Exclusive
Evaluation Option License Agreement
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR Part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
25877
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: May 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–10309 Filed 5–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development (NICHD); Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Child Health and
Human Development Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available. A
portion of this meeting will be closed to
the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review and
discussion of grant applications.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Name of Committee: National Advisory
Child Health and Human Development
Council.
Date: June 5, 2014.
Open: June 5, 2014, 8 a.m. to 12:30 p.m.
Agenda: The agenda will include: Report
of the Director, NICHD; Report of the
Director, DER, NICHD; Statement of
Understanding; Assistive Devices for
Children Update; and the Human Placenta
Project Update.
Closed: June 5, 2014, 1:30 p.m. to
Adjournment.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Center Drive, C-Wing,
Conference Room 10, Bethesda, MD 20892.
Contact Person: Cathy Y. Spong, M.D.,
Director, Division of Extramural Research,
Eunice Kenney Shriver National Institute of
Child Health and Human Development, NIH,
6100 Executive Blvd., Room 4A05, MSC
7510, Bethesda, MD 20892, (301) 435–6894.
Any interested person may file written
comments with the committee by forwarding
the statement to the contact person listed on
E:\FR\FM\06MYN1.SGM
06MYN1
25878
Federal Register / Vol. 79, No. 87 / Tuesday, May 6, 2014 / Notices
this notice. The statement should include the
name, address, telephone number, and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxis, hotel, and airport shuttles,
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
In order to facilitate public attendance at
the open session of Council in the main
meeting room, Conference Room 10, please
contact Ms. Lisa Kaeser, Program and Public
Liaison Office, NICHD, at 301–496–0536 to
make your reservation, additional seating
will be available in the meeting overflow
rooms, Conference Rooms 7 and 8.
Individuals will also be able to view the
meeting via NIH Videocast. Please go to the
following link for Videocast access
instructions at: https://www.nichd.nih.gov/
about/advisory/nachhd/Pages/virtualmeeting.aspx.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment program, National
Institutes of Health, HHS).
Dated: April 30, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–10299 Filed 5–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sroberts on DSK5SPTVN1PROD with NOTICES
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity Applications.
VerDate Mar<15>2010
17:34 May 05, 2014
Jkt 232001
Date: May 28, 2014.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR12–265 NIDDK
Ancillary Studies to Major Ongoing Clinical
Research (RO1): Pharmacogenomics and
Metformin.
Date: June 11, 2014.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Dianne Camp, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 756, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–7682,
campd@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Fellowships in
Digestive Diseases and Nutrition.
Date: June 12, 2014.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Churchill Hotel, 1914 Connecticut
Avenue NW., Washington, DC 20009.
Contact Person: Thomas A. Tatham, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; DDK–C Conflicts.
Date: June 12, 2014.
Time: 4 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Churchill Hotel, 1914 Connecticut
Avenue NW., Washington, DC 20009.
Contact Person: Thomas A. Tatham, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
Dated: April 30, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–10302 Filed 5–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; DEM Fellowship
Review.
Date: June 2–3, 2014.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Churchill Hotel, 1914 Connecticut
Avenue NW., Washington, DC 20009
Contact Person: Carol J. Goter-Robinson,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7791, goterrobinsonc@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK–KUH–
Fellowship Review.
Date: June 3, 2014.
Time: 8 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK–DDK–D
Member Conflict SEP.
Date: June 3, 2014.
E:\FR\FM\06MYN1.SGM
06MYN1
]]>Agencies
[Federal Register Volume 79, Number 87 (Tuesday, May 6, 2014)]
[Notices]
[Pages 25877-25878]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-10299]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD); Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Child Health and Human Development Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. A portion of this meeting will
be closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the
review and discussion of grant applications. Individuals who plan to
attend and need special assistance, such as sign language
interpretation or other reasonable accommodations, should notify the
contact person listed below in advance of the meeting.
Name of Committee: National Advisory Child Health and Human
Development Council.
Date: June 5, 2014.
Open: June 5, 2014, 8 a.m. to 12:30 p.m.
Agenda: The agenda will include: Report of the Director, NICHD;
Report of the Director, DER, NICHD; Statement of Understanding;
Assistive Devices for Children Update; and the Human Placenta
Project Update.
Closed: June 5, 2014, 1:30 p.m. to Adjournment.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, Center Drive,
C-Wing, Conference Room 10, Bethesda, MD 20892.
Contact Person: Cathy Y. Spong, M.D., Director, Division of
Extramural Research, Eunice Kenney Shriver National Institute of
Child Health and Human Development, NIH, 6100 Executive Blvd., Room
4A05, MSC 7510, Bethesda, MD 20892, (301) 435-6894.
Any interested person may file written comments with the
committee by forwarding the statement to the contact person listed
on
[[Page 25878]]
this notice. The statement should include the name, address,
telephone number, and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxis, hotel, and airport shuttles, will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
In order to facilitate public attendance at the open session of
Council in the main meeting room, Conference Room 10, please contact
Ms. Lisa Kaeser, Program and Public Liaison Office, NICHD, at 301-
496-0536 to make your reservation, additional seating will be
available in the meeting overflow rooms, Conference Rooms 7 and 8.
Individuals will also be able to view the meeting via NIH Videocast.
Please go to the following link for Videocast access instructions
at: https://www.nichd.nih.gov/about/advisory/nachhd/Pages/virtual-meeting.aspx.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment program, National
Institutes of Health, HHS).
Dated: April 30, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-10299 Filed 5-5-14; 8:45 am]
BILLING CODE 4140-01-P
